Pexidartinib - Plexxikon

Drug Profile

Pexidartinib - Plexxikon

Alternative Names: Pexidartinib hydrochloride; Plexxikon 3397; PLX-3397

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plexxikon
  • Developer Array BioPharma; AstraZeneca; Barbara Ann Karmanos Cancer Institute; Centre Leon Berard; Columbia University; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Plexxikon; University of California at San Francisco
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorine compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pigmented villonodular synovitis
  • Phase II Alzheimer's disease; Glioblastoma; Malignant melanoma; Prostate cancer
  • Phase I/II Acute myeloid leukaemia; Breast cancer; Leukaemia; Peripheral nervous system diseases; Sarcoma; Solid tumours
  • Phase I Colorectal cancer; Gastrointestinal stromal tumours; Pancreatic cancer
  • No development reported Neurological disorders; Rheumatoid arthritis
  • Discontinued Hodgkin's disease

Most Recent Events

  • 27 Jun 2018 Pexidartinib is still in phase I trials Solid-tumours(Metastatic disease) in USA (PO, Capsule) (NCT01004861)
  • 04 Jun 2018 Daiichi Sankyo plans to submit NDA to US FDA for Pigmented villonodular synovitis and intends to engage with European regulators for review of pexidartinib
  • 04 Jun 2018 Efficacy and adverse events data from the phase III ENLIVEN trial in Pigmented villonodular synovitis presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top